Recursion Pharmaceuticals announced layoffs affecting about 20% of its staff following a strategic pipeline cutback and focus on oncology and rare diseases after merging with Exscientia. The downsizing, amid restructured R&D priorities, signals challenges in maintaining rapid growth in the AI-driven biotech sector.